Posted on February 6, 2009 at 3:44 PM
Filed under: Acquisitions | Growth Strategy | Trends
Tagged: Daniel Vasella , Joe Jimenez , Novartis

[ Share ]  [ E-mail ]  [ Leave a Comment ]

Swiiss healthcare company Novartis AG raised $5 billion through five- and 10-year bond offerings. The firm said the money will be used for general corporate purposes. But being a healthcare company these days -- and given its deal background -- it's not a stretch to think the money might go toward acquisitions. 

A Bloomberg report notes Novartis needs to replace income from the heart medicine Diovan and the Gleevec cancer treatment when patents expire starting in 2012. The article cited comments from CEO Daniel Vasella and drug unit head Joe Jimenez as saying the firm is planning to invest in research and make more acquisitions in the next year than the three purchases it made last year. - Baz Hiralal

Go to the story
Here comes pharma's 'me-too' mergers


Join Corporate Dealmaker's LinkedIn forum

Also From Corporate Dealmaker

• Deal Economy 2010: Cisco's Hooper on Tandberg pursuit
• Deal Economy 2010: IBM's Mendoza on IT services M&A
• Next up on mobile ad acquisitions
• Deal Economy 2010: GE's O'Brien on M&A strategy
• Medtronic earnings reflect strategic maneuvering

Corporate Dealmaker Home Page

From TheDeal.com

• Deal Economy 2010: IBM's Mendoza on IT services M&A
• Deal Stocks: GOOG, BMO, C, PLA, GE, FIF, PBCT
• Joost assets quietly sold to Adconion
• Deal Economy 2010: Streambank's Fried on IP valuations
• Green Mountain raises Diedrich bid

TheDeal.com Home

Post a comment

Name:

Email Address:

URL:

Remember personal info?

Comments: (you may use HTML tags for style)

Please only click "Post" once. It may take a few moments to process.